| 吉非替尼致间质性肺疾病及其防治 |
| |
| 引用本文： | 高璇,李智平.吉非替尼致间质性肺疾病及其防治[J].药物不良反应杂志,2011,13(3):165-168. |
| |
| 作者姓名： | 高璇 李智平 |
| |
| 作者单位： | 复旦大学附属儿科医院药剂科,上海,201102 |
| |
| 摘 要： | 吉非替尼是一种口服选择性表皮生长因子受体酪氨酸激酶抑制剂,用于治疗非小细胞肺癌。吉非替尼可引起间质性肺疾病(ILD),引起ILD的平均时间为24～42d,发生率为0.44%～2.0%,病死率为0.12%～0.5%。ILD主要临床表现为呼吸困难、胸闷、干咳和发绀等,胸部影像学检查可见双肺弥漫性浸润性阴影及蜂窝状间质阴影。高龄、男性、吸烟史、ILD史和长时间用药等为吉非替尼致ILD的危险因素。用药期间应进行胸部影像学检查,一旦发现ILD应及时停药,并给予静脉注射大剂量糖皮质激素、吸氧、抗感染等对症支持治疗,一般预后良好。
|
| 关 键 词： | 间质性肺疾病 吉非替尼 |
Gefitinib-induced interstitial lung disease:prevention and treatment |
| |
| Gao Xuan,Li Zhiping.Gefitinib-induced interstitial lung disease:prevention and treatment[J].Adverse Drug Reactions Journal,2011,13(3):165-168. |
| |
| Authors: | Gao Xuan Li Zhiping |
| |
| Institution: | Gao Xuan,Li Zhiping(Department of Pharmacy,Children's Hospital of Fudan University,Shanghai 201102,China) |
| |
| Abstract: | Gefitinib is a selective inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor,which is used in the treatment of non-small-cell lung cancer.Gefitinib can cause interstitial lung disease(ILD).The mean time to gefitinib-induced ILD onset is 2442 days.The incidence of ILD is 0.44%-2.0%,and the mortality rate of ILD is 0.12%-0.5%.The clinical manifestations are dyspnea,respiratory distress,dry cough,and cyanosis.Diffuse infiltration shadow and alveolar interstitial shadow were seen o... |
| |
| Keywords: | interstitial lung disease gefitinib |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
